PMID: 11902528Mar 21, 2002Paper

The biological treatment of renal-cell carcinoma and melanoma

The Lancet Oncology
Paul D Nathan, Tim G Eisen

Abstract

Biological therapies are claiming a place in the routine management of some solid tumours. In this review we focus on the biological treatment of melanoma and renal-cell carcinoma, identifying the background to current practice and areas of promise that may be in routine clinical use in the near future. Melanomas and renal-cell carcinomas are particularly resistant to chemotherapy and radiotherapy and are characterised by the host immune response to the tumours. For this reason there has been particular interest in the biological therapy of these diseases. Biological therapies differ from chemotherapeutic approaches in their mechanism of action, time to response, and side-effect profiles. Although biological treatment has a long history, it is only with recent advances in immunology and molecular biology that progress has been made. In the next few years investigators expect to build on their research experience with biotherapeutic agents to provide tangible benefits for patients.

References

Jan 1, 1992·Cancer Immunology, Immunotherapy : CII·A S KooA Belldegrum
Aug 1, 1982·Urology·R M Snow, P F Schellhammer
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J D'AmatoJ Folkman
Oct 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S S LeghaN Papadopoulos
Jun 1, 1997·Immunology Today·T BoonB Van den Eynde
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Mar 29, 2001·The New England Journal of Medicine·D L MusselmanA H Miller
Mar 22, 2002·The Lancet Oncology·S R Johnston
Mar 22, 2002·The Lancet Oncology·M JeffordI D Davis

❮ Previous
Next ❯

Citations

Dec 4, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Linda E Bröker, Giuseppe Giaccone
Oct 10, 2002·Clinical and Experimental Dermatology·D SawamuraH Shimizu
Feb 18, 2003·Journal of Internal Medicine·P Nygren, R Larsson
Dec 10, 2003·Journal of Pediatric Hematology/oncology·Kimberly A KasowWing Leung
Aug 19, 2005·Molecular and Cellular Biology·Jiabin An, Matthew B Rettig
Jan 1, 2009·Immunotherapy·Annkristin HeinePeter Brossart
Jul 14, 2004·Chest·Lionel DuckJean-Pascal Machiels
Feb 19, 2008·International Immunopharmacology·Anette SundstedtGunnar Hedlund
Apr 11, 2008·BJU International·Erik G HavranekHardev Pandha
May 6, 2006·European Urology·Annika BerntsenInge Marie Svane
Jan 25, 2006·BJU International·Benjamin W TurneyDavid W Cranston
Dec 4, 2003·Expert Opinion on Biological Therapy·Marko B Lens
Jul 2, 2003·Expert Opinion on Investigational Drugs·Massimo FanelliGiampietro Gasparini
Oct 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger K StrairEdmund C Lattime
Jan 2, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Fabio PastorinoTheresa M Allen
Aug 2, 2011·Nature Reviews. Drug Discovery·W Joost LesterhuisCornelis J A Punt
May 9, 2015·Protoplasma·Jaime A Teixeira da Silva, Judit Dobránszki
Mar 8, 2005·Drug Metabolism Reviews·Shufeng ZhouYu-Zong Chen
Apr 4, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jason M ZimmererWilliam E Carson
Apr 22, 2003·Pathology Oncology Research : POR·József TímárLászló Kopper
Oct 9, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Klaus TenbrockGeorge C Tsokos
Mar 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bernard EscudierCaroline Robert
Apr 9, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Barbara BucciAldo Vecchione
Sep 16, 2004·Seminars in Thoracic and Cardiovascular Surgery·Daniel J MaslyarDavid M Jablons

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.